ODM 106

Drug Profile

ODM 106

Alternative Names: ODM-106

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Class
  • Mechanism of Action GABA B receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Essential tremor

Most Recent Events

  • 27 Jan 2016 Discontinued - Phase-I for Essential tremor (In volunteers) in Germany (PO) (Orion pipeline, January 2016)
  • 01 Jan 2015 Preclinical trials in Essential tremor in Finland (PO) before January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top